Rocket Pharmaceuticals, Inc.
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs f…
Biotechnology
US, Cranbury [HQ]
RCKT/Financial Reporting
Income Statements
Profit & Loss · 12 Statements · From 2023 to 2012Configuration
In Million USD. Margins, Growth Rates In %
| Metric | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
EPS
|
-2.88 | -3.62 | -2.79 | -14.85 | -6.41 | -4.36 | -1.89 | -1.70 | -2.65 | -2.68 | -3.22 | -2.92 | |
| Diluted in mil. | -2.88 | -3.62 | -2.79 | -14.85 | -6.41 | -4.36 | -1.89 | -1.70 | -2.65 | -2.68 | -3.22 | -2.92 | |
|
Profit
|
- - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -5.00 | -6.00 | -7.00 | |
| Gross Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Pre Tax | -6.00 | -7.00 | -9.00 | -67.00 | -42.00 | -29.00 | -74.00 | -77.00 | -139.00 | -169.00 | -221.00 | -245.00 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| ETR | -3.58 | -11.61 | - - | -1.81 | -1.03 | -2.78 | -3.59 | -7.71 | -4.99 | -0.31 | 1.12 | - - | |
| Net | -6.00 | -7.00 | -9.00 | -67.00 | -42.00 | -29.00 | -74.00 | -83.00 | -146.00 | -169.00 | -219.00 | -245.00 | |
| Profit Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| EBITDA | -5.00 | -6.00 | -7.00 | -20.00 | -41.00 | -25.00 | -68.00 | -72.00 | -131.00 | -163.00 | -213.00 | -252.00 | |
| EBITDA Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Operating Income | -5.00 | -6.00 | -7.00 | -20.00 | -41.00 | -26.00 | -71.00 | -76.00 | -134.00 | -167.00 | -224.00 | -259.00 | |
| Operating Margin | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Interest Income | - - | - - | - - | - - | - - | - - | 1.00 | 3.00 | 2.00 | 3.00 | 3.00 | 15.00 | |
| Loss | -5.00 | -6.00 | -7.00 | -20.00 | -41.00 | -26.00 | -70.00 | -75.00 | -134.00 | -166.00 | -223.00 | -259.00 | |
| Cost of Revenue | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -5.00 | -6.00 | -7.00 | |
|
Operating Expenses
|
-5.00 | -6.00 | -7.00 | -20.00 | -41.00 | -26.00 | -70.00 | -75.00 | -134.00 | -166.00 | -223.00 | -252.00 | |
| R&D | -3.00 | -5.00 | -5.00 | -12.00 | -31.00 | -14.00 | -53.00 | -58.00 | -106.00 | -125.00 | -165.00 | -180.00 | |
| G&A | -2.00 | -1.00 | -2.00 | -7.00 | -9.00 | -12.00 | -17.00 | -17.00 | -27.00 | -41.00 | -58.00 | -73.00 | |
| SG&A | -2.00 | -1.00 | -2.00 | -7.00 | -9.00 | -12.00 | -17.00 | -17.00 | -27.00 | -41.00 | -58.00 | -71.00 | |
| S&M | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | |
| Depreciation and Amortization | - - | - - | - - | - - | - - | - - | - - | - - | -1.00 | -5.00 | -6.00 | -7.00 | |
| Interest Expenses | - - | - - | - - | -1.00 | -1.00 | -3.00 | -5.00 | -4.00 | -7.00 | -5.00 | -1.00 | -1.00 | |
| Other Expenses | - - | - - | - - | -46.00 | - - | -2.00 | - - | -1.00 | -5.00 | -1.00 | -2.00 | -14.00 | |
|
WA Shares Outstanding
|
2.00 | 2.00 | 3.00 | 4.00 | 6.00 | 6.00 | 39.00 | 49.00 | 55.00 | 63.00 | 68.00 | 84.00 | |
| Diluted | 2.00 | 2.00 | 3.00 | 4.00 | 6.00 | 6.00 | 39.00 | 49.00 | 55.00 | 63.00 | 68.00 | 84.00 |